News › Industry News, News

ITC Favors Allergan Partner Medytox Over Daewoong in Botulinum Toxin Strain Dispute

July 10, 2020

The U.S. International Trade Commission (ITC) has sided with South Korean drugmaker Medytox Inc. in a dispute, saying its local rival Daewoong Pharmaceutical Co. stole trade secrets on a botulinum toxin strain, industry officials here said Tuesday.
In its preliminary verdict, the ITC also advised that imports of Daewoong Pharmaceutical’s botulinum toxin products be banned in the United States over the next 10 years.Read more at the Yonhap News Agency >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • 10 Marketing Truths Every Aesthetic Practice Needs to Hear Right Now
    • AI, FDA, PDGF: The Talk of MSS
    • Radiologists Warn that Décolletage Filler May Interfere with Breast Cancer Screening
    • The Beauty Health Company (SKIN) Rebrands to SkinHealth Systems
    • Amazon Launches GLP-1 Weight Loss Program with One Medical